pI: 4.7674 |
Length (AA): 184 |
MW (Da): 20133 |
Paralog Number:
0
Signal peptide: N | GPI Anchor: N | Predicted trans-membrane segments: 0
Targets have been classified into druggability groups (DG) according to their druggability score in network driven prioritizations. DGs range from 1 to 5; the higher the group number, the higher the chance of the target to be druggable
Modbase 3D models:
There are 5 models calculated for this protein. More info on
these models, including the
models themselves is available at:
Modbase
Target Beg | Target End | Template | Template Beg | Template End | Identity | Evalue | Model Score | MPQS | zDope |
---|---|---|---|---|---|---|---|---|---|
4 | 98 | 2ctq (A) | 10 | 91 | 28.00 | 0.00000000062 | 0.96 | 0.72 | -0.16 |
13 | 101 | 1hdj () | 2 | 75 | 27.00 | 0 | 0.83 | 0.7 | -0.77 |
9 | 65 | 2ej7 (A) | 5 | 61 | 28.00 | 0.095 | 0.35 | 0.684383 | -0.77 |
14 | 100 | 2ctq (A) | 21 | 93 | 30.00 | 0 | 1 | 0.697026 | -0.3 |
16 | 90 | 1bq0 (A) | 6 | 66 | 46.00 | 0.000083 | 1 | 0.705009 | 0.23 |
Help me make sense of these data.
A more detailed description of these scores is available at the Modbase Model Evaluation Help Pages, and in the papers referenced therein.
PDB Structures:
Upregulation Percent | Ranking | Stage | Dataset |
---|---|---|---|
Upper 80-100% percentile | amastigotes, metacyclic. | Fernandes MC |
Fernandes MC | Dual Transcriptome Profiling of Leishmania-Infected Human Macrophages Reveals Distinct Reprogramming Signatures. |
Ortholog group members (OG5_129180)
Species | Accession | Gene Product |
---|---|---|
Arabidopsis thaliana | AT4G10130 | DNAJ heat shock N-terminal domain-containing protein |
Candida albicans | CaO19.9568 | DnaJ-like protein with potential CSL zinc finger domain similar to S. cerevisiae JJJ3 (YJR097W) |
Candida albicans | CaO19.2018 | DnaJ-like protein with potential CSL zinc finger domain similar to S. cerevisiae JJJ3 (YJR097W) |
Cryptosporidium hominis | Chro.30124 | hypothetical protein |
Cryptosporidium parvum | cgd3_930 | DnaJ domain, possible zf-CSL following |
Dictyostelium discoideum | DDB_G0292980 | DNAJ heat shock N-terminal domain-containing protein |
Drosophila melanogaster | Dmel_CG2911 | CG2911 gene product from transcript CG2911-RB |
Echinococcus granulosus | EgrG_000255600 | Heat shock protein DnaJ |
Echinococcus multilocularis | EmuJ_000255600 | Heat shock protein DnaJ |
Homo sapiens | ENSG00000170946 | DnaJ (Hsp40) homolog, subfamily C, member 24 |
Leishmania braziliensis | LbrM.18.1530 | chaperone protein DNAj, putative |
Leishmania donovani | LdBPK_181470.1 | chaperone protein DnaJ, putative |
Leishmania infantum | LinJ.18.1470 | chaperone protein DNAj, putative |
Leishmania major | LmjF.18.1490 | chaperone protein DNAj, putative |
Leishmania mexicana | LmxM.18.1490 | chaperone protein DNAj, putative |
Mus musculus | ENSMUSG00000027166 | DnaJ (Hsp40) homolog, subfamily C, member 24 |
Oryza sativa | 4347281 | Os09g0460000 |
Oryza sativa | 4345818 | Os08g0474600 |
Onchocerca volvulus | OVOC12585 |
|
Plasmodium berghei | PBANKA_1102500 | DnaJ protein, putative |
Plasmodium falciparum | PF3D7_0502800 | DnaJ protein, putative |
Plasmodium knowlesi | PKNH_1031100 | DnaJ protein, putative |
Plasmodium vivax | PVX_097645 | hypothetical protein, conserved |
Plasmodium yoelii | PY04661 | hypothetical protein |
Saccharomyces cerevisiae | YJR097W | Jjj3p |
Schmidtea mediterranea | mk4.001448.01 | DnaJ homolog subfamily C member 24 |
Trypanosoma brucei gambiense | Tbg972.10.15090 | chaperone protein DNAj, putative |
Trypanosoma brucei | Tb927.10.12530 | chaperone protein DnaJ, putative |
Trypanosoma congolense | TcIL3000_10_11150 | chaperone protein DnaJ, putative |
Trypanosoma cruzi | TcCLB.511261.20 | chaperone DNAJ protein, putative |
Trypanosoma cruzi | TcCLB.509809.20 | chaperone DNAJ protein, putative |
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please contact us.